Globe & Mail 07:31 AM EDT, 06/02/2021 (MT Newswires) -- Skylight Health Group Inc (SHG.V, a multi-state primary care management group in the United States, that saw its shares lose 5.5% here yesterday, on Wednesday announced they have signed a contract with Adagio Therapeutics, Inc. Skylight will enroll patients into the Phase 2/3 trial (EVADE) evaluating Adagio's monoclonal antibody, ADG20, which is designed to be a long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19.
Skylight Health's clinic in Burlington, MA will enroll both existing Skylight Health patients as well as individuals from the general population. The primary endpoint is the proportion of participants with laboratory-confirmed symptomatic COVID-19 through Day 28 for the post-exposure cohort and through six months for the pre-exposure cohort. Participants will be followed for 12 months following receipt of the trial product (ADG20 or placebo). Approximately 100 clinics sites will participate internationally to enroll 6,400 participants for the EVADE trial.
Skylight Health will be responsible for consenting, enrolling, administering the investigational product (or placebo), and following trial participants while monitoring for safety and the onset of any COVID-19-like symptoms.
The company will be compensated for all trial-related activities as part of the agreement with Adagio, with compensation tied directly to successfully enrolling and following research participants. Participants are also compensated for their time in the trial.
Price: 6.45, Change: -0.38, Percent Change: -5.56